





We have decades of experience designing and running complex oncology trials in both early- and late-phase development. Our clients include the NIH (including NCI and AIDS Malignancy Consortium), major foundations, and a growing roster of biotech and pharmaceutical sponsors. We specialize in trial rescue, small patient populations, and global coordination of studies involving cellular and gene therapies.

### Modernizing clinical research with tech and AI

At Emmes, we are modernizing and automating clinical research across the full spectrum of trial activities to operate faster, more efficiently, and with higher quality. We are the industry's first native digital and Al specialty CRO built on a proprietary technology and Al platform.

## **Services Offerings**



Protocol Development & Navigation



Clinical Trial Management



Data Management



Pharmacovigilance



Biostatistics & Bioinformatics



Global Regulatory Affairs



Site Management & Monitoring



Quality Assurance



# What sets us apart?

#### Benefits of our Services

**Global Experience, Local Insight -** We manage trials across North America, Africa, Asia, and Latin America, including underserved regions and vulnerable populations. We've supported trials in high- and low-income settings for both common and rare cancers.

**Broad Partnerships** - Longstanding collaborations with the National Cancer Institute, the AIDS Malignancy Consortium, and foundations like the Melanoma Research Foundation. We bring a deep understanding of academic, government, and industry sponsor needs.

**Expertise in Complex Oncology Trials -** From small patient populations and early-phase designs to large multicenter pivotal trials, our oncology team provides the scientific rigor and operational insight needed for high-quality execution in studies across melanoma, leukemia, lymphoma, myeloma, HPV related tumors, and rare malignancies.

**Scientific Leadership -** Emmes leaders have authored or co-authored hundreds of peer-reviewed oncology publications. Our team includes experts with extensive regulatory, clinical, and statistical experience, often serving as science officers and trial designers for sponsor networks.

## **Highlights Include**

First Melanoma Vaccine Efficacy Trial Published In NEJM - Emmes supported the first randomized Phase II trial to demonstrate melanoma vaccine efficacy, comparing IL-2 +/- peptide vaccine. Results published in New England Journal of Medicine.

AIDS Malignancy Consortium - Operational and statistical support for more than a decade of AMC trials involving Hodgkin's and non-Hodgkin's lymphomas, HPV related cancers, Burkitt's lymphoma, and rare cancers in people living with HIV, including studies in Africa and Latin America.

**Leukemia Expertise Spanning Decades** - Emmes supported leukemia research under NCI's Group C protocols, including pediatric leukemia and rare subtypes. Managed a Secondary AML/MDS registry to capture long-term safety data.

**Breast Cancer Brain Metastases Research -** Supported the Translational Breast Cancer Research Consortium's (TBCRC) studies evaluating novel HER2+ treatment combinations for CNS metastases, resulting in multiple publications in JCO and Clinical Breast Cancer.

**Driving Progress in Hematologic Cancers** - As the Data Coordinating Center for BMT CTN, Emmes supports large-scale, multi-site studies advancing transplant therapies for leukemia, lymphoma, and myeloma.

**Key Statistics** 

250+
Studies Across
The Oncology
Therapeutic Area

45+
Years of Oncology
Experience

Continents Where We've Conducted Studies

Melanoma Centers
Supported
Via National
Consortium

Peer-Reviewed
Oncology Publications
Co-Authored by
Emmes Experts

For additional information on our Oncology Services, please visit www.emmes.com

